Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Oct
30
Today In Oncology
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo